Background: Hyaluronic acid is a recognised noninvasive marker of liver fibrosis.
| INTRODUCTION
One of the main predictors of outcome in liver disease is the stage of liver fibrosis. 1 Liver biopsy remains the gold-standard method for the assessment of liver fibrosis. However, the risks of liver biopsy, sampling variability and interobserver variation are significant limitations. [2] [3] [4] Therefore, it is desirable to develop and validate noninvasive markers for accurate assessment of liver fibrosis that can inform prognosis in liver disease. Hyaluronic acid is a glucosaminoglycan present in connective tissue that is synthesised by mesenchymal cells and almost exclusively cleared by hepatic sinusoidal endothelial cells (approximately 1% undergoes renal excretion). 5, 6 Hyaluronic acid has been extensively investigated as a simple to measure noninvasive marker of fibrosis, with studies showing that it correlates well with the degree of liver fibrosis and predicts the presence of cirrhosis. [5] [6] [7] [8] [9] [10] Despite this there is little published work with regards to its prognostic ability.
Currently available survival scoring systems, such as Child-PughTurcotte (CPT) and the Model for End-stage Liver Disease (MELD), have been extensively validated as accurate predictors of short or mediumterm survival in cirrhotic patients. 11 However, their accuracy is limited in compensated cirrhosis and non-cirrhotic liver disease as they rely on variables that reflect pathophysiological changes associated with advanced disease. 12 As such, no prognostic marker or scoring system exists that encompasses the entire spectrum of liver disease. We hypothesised that serum hyaluronic acid can independently predict outcome as it is a marker of the severity of liver fibrosis.
The aims of this study therefore were to investigate the ability of an index serum hyaluronic acid measurement to independently predict liver-related and all-cause mortality in patients with liver disease.
| ME TH ODS

| Patient demographics and data collection
This was a retrospective single centre cohort study. We interrogated a database of all serum hyaluronic acid levels obtained from patients attending the clinic for assessment of their liver disease, between Patients with a known diagnosis of hepatocellular carcinoma (HCC)
were excluded as it affects survival independent of severity of liver disease. In addition, patients with documented inflammatory arthritis were excluded as they can have elevated hyaluronic acid values unrelated to liver disease.
| Hyaluronic acid assay
Serum hyaluronic acid was measured using a radiometric assay (Pharmacia, Uppsala, Sweden) performed as per manufacturers protocol at the Hepatology laboratory of the University of Edinburgh.
The normal reference range is less than 75 μg/L.
| Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics for and survival. Patients were categorised into quartiles and compared using the Log-Rank test.
As a result of the problem of potential informed censoring in patients that were transplanted, all survival analyses were run with and without the inclusion of transplant patients (n = 29). The results were similar in both approaches (survival data excluding transplant patients not shown).
We explored independent predictors of mortality using Cox's regression and Cox proportional hazards (CPH) survival model.
Harrell's C-statistic or C-index is widely used as a measure of predictive accuracy for survival models. Predicted survival time can be interchangeable with predicted probability of survival in the proportional hazards model. 13, 14 The positive skew in the hyaluronic acid data distribution was transformed using square root ( Figure S1 ). In 
| Ethics
This study was considered to be a retrospective audit by the local ethics committee; hence no formal ethical approval was necessary.
| RESULTS
| Baseline characteristics
Hyaluronic acid levels were available for 615 patients. 26 patients were excluded due to the diagnosis of HCC (19 patients) or inflammatory arthritis (7 patients). Patient characteristics are summarised in Table 1 . 63% of patients were males. The mean and A weak correlation between hyaluronic acid levels and renal function (creatinine and eGFR) was observed within our cohort (Creatinine, Spearman's r −0.07, P = 0.09; eGFR, Spearman's r −0.1, P = 0.01) ( Figure S2 ). This demonstrates that most of the observed variation in hyaluronic acid is not dependent on renal function.
| Serum hyaluronic acid and transplant-free survival
Kaplan-Meier survival analysis of liver-related mortality and all-cause mortality are shown in Figure 3 . Transplant-free survival was On multivariable Cox regression analysis, serum hyaluronic acid, MELD score, age and aetiology of liver disease were independent predictors of transplant-free survival (Table 2) . Female gender was not associated with increased all-cause mortality (P < 0.22), but was associated with increased liver-related mortality (HR 1.58, 95% CI 1.01-2.48, P = 0.04). In the multivariable Cox regression models, there was no interaction between hyaluronic acid and aetiology suggesting that hyaluronic acid predicts outcome independently of diagnosis (data not shown). Figure S4 . Kaplan-Meier survival analysis was used to examine transplant-free survival using both the MELD score (categorised into quartiles) and MELD-hyaluronic acid score (categorised into quartiles). For both the MELD and MELD-hyaluronic acid analyses there were statistically significant differences in survival between quartiles of the score ( Figure 5A ,B, Log Rank P < 0.001). However, the MELD-hyaluronic acid score showed better separation of the four quartile survival curves suggesting that it performs better as a prognostic test.
| Cox proportional hazard survival model
Determining survival using Cox's proportional hazard modelling, Hyaluronic Acid: <100 100-300 >300 F I G U R E 3 A, Hyaluronic acid and Liver-Related Mortality. Kaplan-Meier survival analysis: hyaluronic acid categorised into 3 groups (<100 μg/L, 100-300 μg/L and >300 μg/L). Log Rank (P < 0.001). B, Hyaluronic acid and all-cause mortality. Kaplan-Meier survival analysis: hyaluronic acid categorised into 3 groups (<100 μg/L, 100-300 μg/L and >300 μg/L). Log Rank (P < 0.001)
| DISCUSSION
In this study, we found that an index serum hyaluronic acid level can accurately predict transplant-free survival in patients with liver disease. Using regression modelling we have also shown that serum hyaluronic acid predicts liver-related as well as all-cause mortality independent of MELD, age and aetiology. To our knowledge this is the largest study investigating the prognostic ability of an index serum hyaluronic acid in a cohort of liver disease patients with varying aetiologies and severity.
Hyaluronic acid has been shown to accurately correlate with the degree of liver fibrosis. 10 Levels >100 μg/L have been shown to be 78% specific and 83% sensitive at predicting underlying cirrhosis with the specificity increasing to 98% when a cut-off >300 μg/L is used. 10 In addition, hyaluronic acid levels have been shown to correlate with the severity of cirrhosis. 10 As the best prognostic marker in liver disease is the extent of underlying fibrosis, it is not surprising that patients with hyaluronic acid levels >300 μg/L and thus likely to have advanced cirrhosis, have a significantly higher 5-year liverrelated mortality (35%) compared to those with levels of 100-300 μg/L (9%) and <100 μg/L (3%) [χ 2 = 52, P < 0.001]. The survival differences observed between hyaluronic acid groups continued throughout follow up (Figure 3) . Furthermore, on multivariable regression analysis hyaluronic acid performed independently of aetiology (Table 2) . These results support the use of hyaluronic acid as a tool that can be extrapolated to patients with varying aetiologies and severities of liver disease, allowing risk stratification but also offering a degree of reassurance that death from liver disease is unlikely in patients with hyaluronic acid levels <100 μg/L. Furthermore, on survival CPH modelling, hyaluronic acid accurately predicts higher transplant-free survival in lower serum concentration; and higher liver-related mortality with higher serum hyaluronic acid levels.
The current National Institute for Health and Care Excellence (NICE) guidelines for NAFLD recommend the use of the Enhanced Liver Fibrosis (ELF) score to test for advanced fibrosis. 15 The ELF score which is a patented noninvasive panel of extracellular matrix markers including hyaluronic acid and has been shown to accurately correlate with varying degrees of liver fibrosis and to predict liverrelated morbidity and mortality at least as well as biopsy in a range of liver diseases. 16 However, limited availability as well as significant costs restrict its use. Direct comparison of hyaluronic acid with the ELF score within our cohort was limited by the availability of data.
Nonetheless, hyaluronic acid may offer a good alternative as a noninvasive marker of fibrosis due to its significant prognostic capability but also ease of measurement with a short turn around and at a significantly lower cost.
The MELD score was calculated for each patient using parameters at the point of hyaluronic acid testing. We recognise that the MELD score has been validated for patients with cirrhosis and thus applying it to a cohort with varying degrees of liver fibrosis will artificially lower its prognostic value. 11 Despite this, our model identified the MELD score as an independent and accurate predictor of mortality, with survival analysis showing that liver-related mortality was significantly higher with increasing MELD quartiles ( Excluded from model P = 0. 17 In patients with primary biliary cholangitis, Nyberg et al also revealed hyaluronic acid negatively correlated with survival time. 18 Furthermore, modification of the CP score by addition of hyaluronic acid has been shown to increase its prognostic power, especially in alcoholic aetiology. 19 In addition to a single measurement, rate of change in hyaluronic acid has been shown to be associated with higher incidence of liver-related adverse events. 20 Authors have demonstrated hyaluronic acid as part of a model, predictive of liver-related adverse events. 21 Our results add to the existing weight of evidence whilst demonstrating that the use of index hyaluronic acid alone is a reliable prognostic marker; applicable across various aetiologies of liver disease and severity.
We recognised several study limitations. Firstly, this was a retrospective analysis although all data was prospectively collected. Alcohol status was also not controlled for due to the difficulties of ALD group (Figure 2 ). 22 However, the patients with ALD had higher MELD scores as well as mortality compared to other aetiologies (Figure 2 , Figure S3 ). Furthermore, hyaluronic acid levels performed independently of aetiology suggesting that the higher levels observed may be due to more advanced disease in the ALD group.
Inaccuracies in the documentation of liver disease on death certificates are also to be expected, although hyaluronic acid also predicted all-cause mortality. Individuals with arthritis may have falsely elevated hyaluronic acid levels and although patients with documented rheumatic diseases were excluded from our analysis, patients with undiagnosed disease may have been included. The number of patients in the group with hyaluronic acid levels <100 μg/L was considerably less compared with those between 100 and 300 μg/L or >300 μg/L. This likely reflects selection bias in patients who are attending the liver clinic and are therefore more likely to have advanced disease. Finally, lack of serial hyaluronic acid measurements reduced our ability to reliably determine the influence of hyaluronic acid changes with time on outcomes.
In conclusion, we have demonstrated the accuracy through survival models and prognostic abilities of hyaluronic acid in patients with liver disease attending the liver clinic. Hyaluronic acid is a simple and potentially readily available test that can accurately predict survival in liver disease of varying severity. A value of hyaluronic acid <100 μg/L is reassuring and is associated with favourable survival. Furthermore, the addition of hyaluronic acid to the MELD may allow further prognostication in the general liver disease population.
Further prospective studies are required to validate these results and directly compare hyaluronic acid with other noninvasive markers of liver fibrosis before fully establishing its prognostic value.
